Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution...

FDA Recall #D-0404-2022 — Class II — December 6, 2021

Recall #D-0404-2022 Date: December 6, 2021 Classification: Class II Status: Terminated

Product Description

Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18

Reason for Recall

Lack of Assurance of Sterility

Recalling Firm

Edge Pharma, LLC — Colchester, VT

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

1202 syringes

Distribution

nationwide

Code Information

10-2021-26@3 12/04/2021 11-2021-09@1 12/23/2021

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated